Korro Bio, Inc. Common Stock earnings per share and revenue
On 12 de nov. de 2025, KRRO reported earnings of -1.92 USD per share (EPS) for Q3 25, beating the estimate of -2.64 USD, resulting in a 27.43% surprise. Revenue reached 1.09 milhão, compared to an expected 589.78 mil, with a 84.81% difference. The market reacted with a -79.31% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analistas forecast an EPS of -2.16 USD, with revenue projected to reach 708.17 mil USD, implying an aumentar of 12.50% EPS, and diminuir of -35.03% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
What were Korro Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Korro Bio, Inc. Common Stock reported EPS of -$1.92, beating estimates by 27.43%, and revenue of $1.09M, 84.81% above expectations.
How did the market react to Korro Bio, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -79.31%, changed from $31.42 before the earnings release to $6.50 the day after.
When is Korro Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for 16 de mar. de 2026.
What are the forecasts for Korro Bio, Inc. Common Stock's next earnings report?
Based on 12
analistas, Korro Bio, Inc. Common Stock is expected to report EPS of -$2.16 and revenue of $708.17K for Q4 2025.